"Benzimidazole Derived Non-CDN STING Agonists: Mechanisms, SAR Evolution, and Therapeutic Potential - A Comprehensive Review".

The Stimulator of interferon genes (STING) pathway plays a vital role in activating innate immune responses, making it a promising target for cancer immunotherapy. While traditional STING agonists, such as cyclic dinucleotides (CDNs) have shown strong anti-tumor potential, their clinical use is limited due to poor cell permeability, rapid breakdown in the body, and low bioavailability. To overcome these challenges, researchers have focused on developing non-CDN STING agonists, with benzimidazole derivatives emerging as highly promising alternatives. These small molecules offer greater stability, improved pharmacokinetics, and the potential for oral administration, making them more suitable for therapeutic use. This review explores recent advancements in benzimidazole-based STING agonists, highlighting their structural and functional properties, structure activity relationship insights, and mechanism of action. By optimizing their design, scientists have enhanced their ability to trigger immune responses, boost interferon production, and improve overall therapeutic effectiveness. The rise of these novel STING agonists marks an exciting shift in immune-oncology, offering hope for more effective, long-lasting cancer therapies. With their potential to improve patient outcomes and expand treatment options, benzimidazole-based STING agonists offer new hope in the fight against cancer.